McKesson Corporation (MCK)
NYSE: MCK · Real-Time Price · USD
934.75
+18.75 (2.05%)
At close: Feb 13, 2026, 4:00 PM EST
933.08
-1.67 (-0.18%)
After-hours: Feb 13, 2026, 7:55 PM EST
Revenue
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
| TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|
| Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 |
|---|
Prescription Technology Solutions Revenue | 5.65B | 5.22B | 4.77B | | | | | | | |
Prescription Technology Solutions Revenue Growth | 8.30% | 9.37% | 8.71% | | | | | | | |
Medical Surgical Solutions Revenue | 11.49B | 11.39B | 11.31B | | | | | | | |
Medical Surgical Solutions Revenue Growth | 0.93% | 0.65% | 1.83% | | | | | | | |
US Pharmaceutical Revenue | - | 327.72B | 278.74B | | | | | | | |
US Pharmaceutical Revenue Growth | - | 17.57% | 15.84% | | | | | | | |
| - | 14.72B | 14.13B | | | | | | | |
International Revenue Growth | - | 4.18% | -31.40% | | | | | | | |
| 397.96B | 359.05B | 308.95B | | | | | | | |
| 10.84% | 16.22% | 11.65% | | | | | | | |
EBIT
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
| TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|
| Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 |
|---|
Prescription Technology Solutions Operating Profit | 1.01B | 875.00M | 835.00M | | | | | | | |
Prescription Technology Solutions Operating Profit Growth | 14.97% | 4.79% | 47.53% | | | | | | | |
Medical Surgical Solutions Operating Profit | 933.00M | 773.00M | 952.00M | | | | | | | |
Medical Surgical Solutions Operating Profit Growth | 20.70% | -18.80% | -14.77% | | | | | | | |
US Pharmaceutical Operating Profit | - | 4.00B | 2.79B | | | | | | | |
US Pharmaceutical Operating Profit Growth | - | 43.65% | -13.10% | | | | | | | |
International Operating Profit | - | -213.00M | 319.00M | | | | | | | |
International Operating Profit Growth | - | - | 134.56% | | | | | | | |
| 3.71B | -1.02B | -983.00M | | | | | | | |
| 5.65B | 4.42B | 3.91B | | | | | | | |
Operating Income (Total) Growth | 27.84% | 13.12% | -10.77% | | | | | | | |
Capital Expenditures
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|
| Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | Mar '19 Mar 31, 2019 | Mar '18 Mar 31, 2018 | Mar '17 Mar 31, 2017 |
|---|
US Pharmaceutical Capital Expenditures | 241.00M | 193.00M | | | | | | | |
US Pharmaceutical Capital Expenditures Growth | 24.87% | 25.32% | | | | | | | |
Prescription Technology Solutions Capital Expenditures | 11.00M | 31.00M | | | | | | | |
Prescription Technology Solutions Capital Expenditures Growth | -64.52% | -11.43% | | | | | | | |
Medical Surgical Solutions Capital Expenditures | 163.00M | 159.00M | | | | | | | |
Medical Surgical Solutions Capital Expenditures Growth | 2.52% | 35.90% | | | | | | | |
International Capital Expenditures | 107.00M | 75.00M | | | | | | | |
International Capital Expenditures Growth | 42.67% | -5.06% | | | | | | | |
Updated Feb 4, 2026. Data Source:
Fiscal.ai.
